Clinical Trial Update: Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ribavirin and Hedgehog pathway inhibitor with or without decitabine in acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Decitabine (Decitabine)
• Hedgehog pathway inhibitor
• Ribavirin (ribavirin)

Snippet

Sponsor: Sarit Assouline | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED